nodes	percent_of_prediction	percent_of_DWPC	metapath
Duloxetine—Hyperkeratosis—Cyclosporine—focal segmental glomerulosclerosis	0.0309	0.0349	CcSEcCtD
Duloxetine—Pharyngeal oedema—Cyclosporine—focal segmental glomerulosclerosis	0.0309	0.0349	CcSEcCtD
Duloxetine—Traumatic liver injury—Cyclosporine—focal segmental glomerulosclerosis	0.0237	0.0268	CcSEcCtD
Duloxetine—Nephropathy—Cyclosporine—focal segmental glomerulosclerosis	0.0185	0.021	CcSEcCtD
Duloxetine—Night sweats—Cyclosporine—focal segmental glomerulosclerosis	0.0164	0.0185	CcSEcCtD
Duloxetine—Micturition urgency—Cyclosporine—focal segmental glomerulosclerosis	0.0156	0.0176	CcSEcCtD
Duloxetine—Hypertriglyceridaemia—Cyclosporine—focal segmental glomerulosclerosis	0.0154	0.0174	CcSEcCtD
Duloxetine—Gastric ulcer—Cyclosporine—focal segmental glomerulosclerosis	0.0152	0.0172	CcSEcCtD
Duloxetine—Blood triglycerides increased—Cyclosporine—focal segmental glomerulosclerosis	0.0135	0.0152	CcSEcCtD
Duloxetine—Menstrual disorder—Cyclosporine—focal segmental glomerulosclerosis	0.013	0.0146	CcSEcCtD
Duloxetine—Hyperlipidaemia—Cyclosporine—focal segmental glomerulosclerosis	0.0122	0.0139	CcSEcCtD
Duloxetine—Hepatotoxicity—Cyclosporine—focal segmental glomerulosclerosis	0.0114	0.0129	CcSEcCtD
Duloxetine—Skin ulcer—Cyclosporine—focal segmental glomerulosclerosis	0.0113	0.0128	CcSEcCtD
Duloxetine—HTR2A—Serotonin Receptor 2 and STAT3 Signaling—GNAQ—focal segmental glomerulosclerosis	0.0113	0.0974	CbGpPWpGaD
Duloxetine—Feeling hot—Cyclosporine—focal segmental glomerulosclerosis	0.0112	0.0127	CcSEcCtD
Duloxetine—Gingivitis—Cyclosporine—focal segmental glomerulosclerosis	0.0112	0.0127	CcSEcCtD
Duloxetine—Rigors—Cyclosporine—focal segmental glomerulosclerosis	0.0108	0.0122	CcSEcCtD
Duloxetine—Liver injury—Cyclosporine—focal segmental glomerulosclerosis	0.0105	0.0119	CcSEcCtD
Duloxetine—Disturbance in attention—Cyclosporine—focal segmental glomerulosclerosis	0.0102	0.0115	CcSEcCtD
Duloxetine—Rhabdomyolysis—Cyclosporine—focal segmental glomerulosclerosis	0.00998	0.0113	CcSEcCtD
Duloxetine—Musculoskeletal stiffness—Cyclosporine—focal segmental glomerulosclerosis	0.00984	0.0111	CcSEcCtD
Duloxetine—Nocturia—Cyclosporine—focal segmental glomerulosclerosis	0.00952	0.0108	CcSEcCtD
Duloxetine—Eructation—Cyclosporine—focal segmental glomerulosclerosis	0.00867	0.00981	CcSEcCtD
Duloxetine—Influenza like illness—Cyclosporine—focal segmental glomerulosclerosis	0.00857	0.0097	CcSEcCtD
Duloxetine—Urinary incontinence—Cyclosporine—focal segmental glomerulosclerosis	0.00853	0.00964	CcSEcCtD
Duloxetine—Nightmare—Cyclosporine—focal segmental glomerulosclerosis	0.00853	0.00964	CcSEcCtD
Duloxetine—Urine output increased—Cyclosporine—focal segmental glomerulosclerosis	0.00798	0.00903	CcSEcCtD
Duloxetine—Lymphadenopathy—Cyclosporine—focal segmental glomerulosclerosis	0.00751	0.0085	CcSEcCtD
Duloxetine—Diabetes mellitus—Cyclosporine—focal segmental glomerulosclerosis	0.00737	0.00833	CcSEcCtD
Duloxetine—Polyuria—Cyclosporine—focal segmental glomerulosclerosis	0.0073	0.00825	CcSEcCtD
Duloxetine—Gastroenteritis—Cyclosporine—focal segmental glomerulosclerosis	0.00723	0.00818	CcSEcCtD
Duloxetine—Disorientation—Cyclosporine—focal segmental glomerulosclerosis	0.00716	0.0081	CcSEcCtD
Duloxetine—Eczema—Cyclosporine—focal segmental glomerulosclerosis	0.00713	0.00807	CcSEcCtD
Duloxetine—Hepatic failure—Cyclosporine—focal segmental glomerulosclerosis	0.00713	0.00807	CcSEcCtD
Duloxetine—Libido decreased—Cyclosporine—focal segmental glomerulosclerosis	0.00691	0.00782	CcSEcCtD
Duloxetine—Hot flush—Cyclosporine—focal segmental glomerulosclerosis	0.00685	0.00775	CcSEcCtD
Duloxetine—NPY1R—Endothelin Pathways—EDN1—focal segmental glomerulosclerosis	0.00685	0.0592	CbGpPWpGaD
Duloxetine—Increased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.00682	0.00771	CcSEcCtD
Duloxetine—Menopausal symptoms—Cyclosporine—focal segmental glomerulosclerosis	0.00679	0.00768	CcSEcCtD
Duloxetine—Visual disturbance—Cyclosporine—focal segmental glomerulosclerosis	0.00676	0.00765	CcSEcCtD
Duloxetine—Renal impairment—Cyclosporine—focal segmental glomerulosclerosis	0.00673	0.00762	CcSEcCtD
Duloxetine—Hypoglycaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00657	0.00743	CcSEcCtD
Duloxetine—Cardiac failure—Cyclosporine—focal segmental glomerulosclerosis	0.00657	0.00743	CcSEcCtD
Duloxetine—Lethargy—Cyclosporine—focal segmental glomerulosclerosis	0.00654	0.0074	CcSEcCtD
Duloxetine—Osteoarthritis—Cyclosporine—focal segmental glomerulosclerosis	0.00641	0.00725	CcSEcCtD
Duloxetine—Disturbance in sexual arousal—Cyclosporine—focal segmental glomerulosclerosis	0.00636	0.00719	CcSEcCtD
Duloxetine—Migraine—Cyclosporine—focal segmental glomerulosclerosis	0.00631	0.00713	CcSEcCtD
Duloxetine—Affect lability—Cyclosporine—focal segmental glomerulosclerosis	0.00631	0.00713	CcSEcCtD
Duloxetine—Mood swings—Cyclosporine—focal segmental glomerulosclerosis	0.00607	0.00687	CcSEcCtD
Duloxetine—Blood creatinine increased—Cyclosporine—focal segmental glomerulosclerosis	0.006	0.00679	CcSEcCtD
Duloxetine—Abdominal pain upper—Cyclosporine—focal segmental glomerulosclerosis	0.00585	0.00662	CcSEcCtD
Duloxetine—Breast disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00579	0.00655	CcSEcCtD
Duloxetine—Cramp muscle—Cyclosporine—focal segmental glomerulosclerosis	0.00577	0.00653	CcSEcCtD
Duloxetine—Gastritis—Cyclosporine—focal segmental glomerulosclerosis	0.00567	0.00641	CcSEcCtD
Duloxetine—Muscular weakness—Cyclosporine—focal segmental glomerulosclerosis	0.00565	0.00639	CcSEcCtD
Duloxetine—Dysphagia—Cyclosporine—focal segmental glomerulosclerosis	0.00554	0.00626	CcSEcCtD
Duloxetine—NPY1R—Peptide GPCRs—AGTR2—focal segmental glomerulosclerosis	0.00551	0.0476	CbGpPWpGaD
Duloxetine—Pancreatitis—Cyclosporine—focal segmental glomerulosclerosis	0.00543	0.00614	CcSEcCtD
Duloxetine—Sweating increased—Cyclosporine—focal segmental glomerulosclerosis	0.0054	0.0061	CcSEcCtD
Duloxetine—Abdominal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.00531	0.00601	CcSEcCtD
Duloxetine—Dysuria—Cyclosporine—focal segmental glomerulosclerosis	0.00518	0.00586	CcSEcCtD
Duloxetine—Upper respiratory tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.00515	0.00582	CcSEcCtD
Duloxetine—Pollakiuria—Cyclosporine—focal segmental glomerulosclerosis	0.00512	0.00579	CcSEcCtD
Duloxetine—Weight increased—Cyclosporine—focal segmental glomerulosclerosis	0.00504	0.0057	CcSEcCtD
Duloxetine—Weight decreased—Cyclosporine—focal segmental glomerulosclerosis	0.00501	0.00567	CcSEcCtD
Duloxetine—Hyperglycaemia—Cyclosporine—focal segmental glomerulosclerosis	0.005	0.00565	CcSEcCtD
Duloxetine—Infestation—Cyclosporine—focal segmental glomerulosclerosis	0.00494	0.00559	CcSEcCtD
Duloxetine—Infestation NOS—Cyclosporine—focal segmental glomerulosclerosis	0.00494	0.00559	CcSEcCtD
Duloxetine—Acute coronary syndrome—Cyclosporine—focal segmental glomerulosclerosis	0.00487	0.00551	CcSEcCtD
Duloxetine—Renal failure—Cyclosporine—focal segmental glomerulosclerosis	0.00486	0.00549	CcSEcCtD
Duloxetine—Myocardial infarction—Cyclosporine—focal segmental glomerulosclerosis	0.00484	0.00548	CcSEcCtD
Duloxetine—Jaundice—Cyclosporine—focal segmental glomerulosclerosis	0.00481	0.00544	CcSEcCtD
Duloxetine—Stomatitis—Cyclosporine—focal segmental glomerulosclerosis	0.00481	0.00544	CcSEcCtD
Duloxetine—Urinary tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.0048	0.00543	CcSEcCtD
Duloxetine—Conjunctivitis—Cyclosporine—focal segmental glomerulosclerosis	0.0048	0.00543	CcSEcCtD
Duloxetine—Hepatobiliary disease—Cyclosporine—focal segmental glomerulosclerosis	0.00467	0.00528	CcSEcCtD
Duloxetine—Epistaxis—Cyclosporine—focal segmental glomerulosclerosis	0.00466	0.00527	CcSEcCtD
Duloxetine—Haemoglobin—Cyclosporine—focal segmental glomerulosclerosis	0.00446	0.00504	CcSEcCtD
Duloxetine—Haemorrhage—Cyclosporine—focal segmental glomerulosclerosis	0.00443	0.00501	CcSEcCtD
Duloxetine—Hepatitis—Cyclosporine—focal segmental glomerulosclerosis	0.00443	0.00501	CcSEcCtD
Duloxetine—Hypoaesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.00441	0.00499	CcSEcCtD
Duloxetine—Pharyngitis—Cyclosporine—focal segmental glomerulosclerosis	0.0044	0.00498	CcSEcCtD
Duloxetine—Urinary tract disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00438	0.00495	CcSEcCtD
Duloxetine—Connective tissue disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00436	0.00493	CcSEcCtD
Duloxetine—Urethral disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00435	0.00492	CcSEcCtD
Duloxetine—Visual impairment—Cyclosporine—focal segmental glomerulosclerosis	0.00427	0.00483	CcSEcCtD
Duloxetine—NPY1R—Peptide GPCRs—AGTR1—focal segmental glomerulosclerosis	0.00424	0.0366	CbGpPWpGaD
Duloxetine—Tinnitus—Cyclosporine—focal segmental glomerulosclerosis	0.00413	0.00468	CcSEcCtD
Duloxetine—Flushing—Cyclosporine—focal segmental glomerulosclerosis	0.00411	0.00465	CcSEcCtD
Duloxetine—Angiopathy—Cyclosporine—focal segmental glomerulosclerosis	0.00402	0.00455	CcSEcCtD
Duloxetine—Mediastinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.004	0.00452	CcSEcCtD
Duloxetine—Chills—Cyclosporine—focal segmental glomerulosclerosis	0.00398	0.0045	CcSEcCtD
Duloxetine—Arrhythmia—Cyclosporine—focal segmental glomerulosclerosis	0.00396	0.00448	CcSEcCtD
Duloxetine—Alopecia—Cyclosporine—focal segmental glomerulosclerosis	0.00392	0.00443	CcSEcCtD
Duloxetine—Mental disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00388	0.00439	CcSEcCtD
Duloxetine—Malnutrition—Cyclosporine—focal segmental glomerulosclerosis	0.00386	0.00437	CcSEcCtD
Duloxetine—Flatulence—Cyclosporine—focal segmental glomerulosclerosis	0.0038	0.0043	CcSEcCtD
Duloxetine—Tension—Cyclosporine—focal segmental glomerulosclerosis	0.00379	0.00428	CcSEcCtD
Duloxetine—Dysgeusia—Cyclosporine—focal segmental glomerulosclerosis	0.00378	0.00427	CcSEcCtD
Duloxetine—Nervousness—Cyclosporine—focal segmental glomerulosclerosis	0.00375	0.00424	CcSEcCtD
Duloxetine—Muscle spasms—Cyclosporine—focal segmental glomerulosclerosis	0.00371	0.0042	CcSEcCtD
Duloxetine—Vision blurred—Cyclosporine—focal segmental glomerulosclerosis	0.00364	0.00411	CcSEcCtD
Duloxetine—Tremor—Cyclosporine—focal segmental glomerulosclerosis	0.00362	0.00409	CcSEcCtD
Duloxetine—HTR2C—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—GNAQ—focal segmental glomerulosclerosis	0.00358	0.0309	CbGpPWpGaD
Duloxetine—Ill-defined disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00358	0.00405	CcSEcCtD
Duloxetine—Anaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00357	0.00403	CcSEcCtD
Duloxetine—Agitation—Cyclosporine—focal segmental glomerulosclerosis	0.00355	0.00401	CcSEcCtD
Duloxetine—Angioedema—Cyclosporine—focal segmental glomerulosclerosis	0.00353	0.00399	CcSEcCtD
Duloxetine—Malaise—Cyclosporine—focal segmental glomerulosclerosis	0.00348	0.00394	CcSEcCtD
Duloxetine—Vertigo—Cyclosporine—focal segmental glomerulosclerosis	0.00347	0.00392	CcSEcCtD
Duloxetine—Leukopenia—Cyclosporine—focal segmental glomerulosclerosis	0.00345	0.00391	CcSEcCtD
Duloxetine—Cough—Cyclosporine—focal segmental glomerulosclerosis	0.00337	0.00381	CcSEcCtD
Duloxetine—Convulsion—Cyclosporine—focal segmental glomerulosclerosis	0.00334	0.00378	CcSEcCtD
Duloxetine—Hypertension—Cyclosporine—focal segmental glomerulosclerosis	0.00333	0.00377	CcSEcCtD
Duloxetine—Chest pain—Cyclosporine—focal segmental glomerulosclerosis	0.00329	0.00372	CcSEcCtD
Duloxetine—Myalgia—Cyclosporine—focal segmental glomerulosclerosis	0.00329	0.00372	CcSEcCtD
Duloxetine—Arthralgia—Cyclosporine—focal segmental glomerulosclerosis	0.00329	0.00372	CcSEcCtD
Duloxetine—Anxiety—Cyclosporine—focal segmental glomerulosclerosis	0.00327	0.0037	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—focal segmental glomerulosclerosis	0.00326	0.00369	CcSEcCtD
Duloxetine—Discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.00325	0.00367	CcSEcCtD
Duloxetine—Dry mouth—Cyclosporine—focal segmental glomerulosclerosis	0.00321	0.00363	CcSEcCtD
Duloxetine—Confusional state—Cyclosporine—focal segmental glomerulosclerosis	0.00318	0.00359	CcSEcCtD
Duloxetine—Anaphylactic shock—Cyclosporine—focal segmental glomerulosclerosis	0.00315	0.00356	CcSEcCtD
Duloxetine—Oedema—Cyclosporine—focal segmental glomerulosclerosis	0.00315	0.00356	CcSEcCtD
Duloxetine—Infection—Cyclosporine—focal segmental glomerulosclerosis	0.00313	0.00354	CcSEcCtD
Duloxetine—HTR2A—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—GNAQ—focal segmental glomerulosclerosis	0.00311	0.0269	CbGpPWpGaD
Duloxetine—Nervous system disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00309	0.00349	CcSEcCtD
Duloxetine—Thrombocytopenia—Cyclosporine—focal segmental glomerulosclerosis	0.00308	0.00349	CcSEcCtD
Duloxetine—Skin disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00306	0.00346	CcSEcCtD
Duloxetine—Hyperhidrosis—Cyclosporine—focal segmental glomerulosclerosis	0.00305	0.00344	CcSEcCtD
Duloxetine—Anorexia—Cyclosporine—focal segmental glomerulosclerosis	0.003	0.0034	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.00287	0.00325	CcSEcCtD
Duloxetine—Insomnia—Cyclosporine—focal segmental glomerulosclerosis	0.00285	0.00322	CcSEcCtD
Duloxetine—Paraesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.00283	0.0032	CcSEcCtD
Duloxetine—Somnolence—Cyclosporine—focal segmental glomerulosclerosis	0.0028	0.00317	CcSEcCtD
Duloxetine—Dyspepsia—Cyclosporine—focal segmental glomerulosclerosis	0.00277	0.00314	CcSEcCtD
Duloxetine—Decreased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.00274	0.0031	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00272	0.00308	CcSEcCtD
Duloxetine—Fatigue—Cyclosporine—focal segmental glomerulosclerosis	0.00272	0.00307	CcSEcCtD
Duloxetine—Pain—Cyclosporine—focal segmental glomerulosclerosis	0.00269	0.00305	CcSEcCtD
Duloxetine—Constipation—Cyclosporine—focal segmental glomerulosclerosis	0.00269	0.00305	CcSEcCtD
Duloxetine—Feeling abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.0026	0.00294	CcSEcCtD
Duloxetine—NPY1R—Peptide ligand-binding receptors—AGTR2—focal segmental glomerulosclerosis	0.00259	0.0224	CbGpPWpGaD
Duloxetine—Gastrointestinal pain—Cyclosporine—focal segmental glomerulosclerosis	0.00258	0.00291	CcSEcCtD
Duloxetine—Urticaria—Cyclosporine—focal segmental glomerulosclerosis	0.0025	0.00283	CcSEcCtD
Duloxetine—Abdominal pain—Cyclosporine—focal segmental glomerulosclerosis	0.00249	0.00282	CcSEcCtD
Duloxetine—Body temperature increased—Cyclosporine—focal segmental glomerulosclerosis	0.00249	0.00282	CcSEcCtD
Duloxetine—Hypersensitivity—Cyclosporine—focal segmental glomerulosclerosis	0.00232	0.00262	CcSEcCtD
Duloxetine—SLC6A4—Monoamine Transport—AGT—focal segmental glomerulosclerosis	0.00228	0.0197	CbGpPWpGaD
Duloxetine—Asthenia—Cyclosporine—focal segmental glomerulosclerosis	0.00226	0.00256	CcSEcCtD
Duloxetine—Pruritus—Cyclosporine—focal segmental glomerulosclerosis	0.00223	0.00252	CcSEcCtD
Duloxetine—NPY1R—G alpha (i) signalling events—AGTR2—focal segmental glomerulosclerosis	0.00219	0.0189	CbGpPWpGaD
Duloxetine—Diarrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.00216	0.00244	CcSEcCtD
Duloxetine—Dizziness—Cyclosporine—focal segmental glomerulosclerosis	0.00208	0.00236	CcSEcCtD
Duloxetine—NPY1R—GPCRs, Class A Rhodopsin-like—AGTR2—focal segmental glomerulosclerosis	0.00203	0.0175	CbGpPWpGaD
Duloxetine—Vomiting—Cyclosporine—focal segmental glomerulosclerosis	0.002	0.00227	CcSEcCtD
Duloxetine—NPY1R—Peptide ligand-binding receptors—AGTR1—focal segmental glomerulosclerosis	0.00199	0.0172	CbGpPWpGaD
Duloxetine—Rash—Cyclosporine—focal segmental glomerulosclerosis	0.00199	0.00225	CcSEcCtD
Duloxetine—Dermatitis—Cyclosporine—focal segmental glomerulosclerosis	0.00198	0.00224	CcSEcCtD
Duloxetine—Headache—Cyclosporine—focal segmental glomerulosclerosis	0.00197	0.00223	CcSEcCtD
Duloxetine—SLC6A2—Monoamine Transport—AGT—focal segmental glomerulosclerosis	0.00196	0.017	CbGpPWpGaD
Duloxetine—Nausea—Cyclosporine—focal segmental glomerulosclerosis	0.00187	0.00212	CcSEcCtD
Duloxetine—SLC6A3—Monoamine Transport—AGT—focal segmental glomerulosclerosis	0.00174	0.015	CbGpPWpGaD
Duloxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—AGTR2—focal segmental glomerulosclerosis	0.00174	0.015	CbGpPWpGaD
Duloxetine—NPY1R—Peptide ligand-binding receptors—EDN1—focal segmental glomerulosclerosis	0.00169	0.0146	CbGpPWpGaD
Duloxetine—NPY1R—GPCRs, Class A Rhodopsin-like—AGTR1—focal segmental glomerulosclerosis	0.00156	0.0135	CbGpPWpGaD
Duloxetine—NPY1R—Peptide ligand-binding receptors—AGT—focal segmental glomerulosclerosis	0.0014	0.0121	CbGpPWpGaD
Duloxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—AGTR1—focal segmental glomerulosclerosis	0.00134	0.0115	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—AGTR2—focal segmental glomerulosclerosis	0.00132	0.0114	CbGpPWpGaD
Duloxetine—NPY1R—G alpha (i) signalling events—AGT—focal segmental glomerulosclerosis	0.00118	0.0102	CbGpPWpGaD
Duloxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—EDN1—focal segmental glomerulosclerosis	0.00113	0.00978	CbGpPWpGaD
Duloxetine—CYP2D6—Melatonin metabolism and effects—EDN1—focal segmental glomerulosclerosis	0.00106	0.00918	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—AGTR1—focal segmental glomerulosclerosis	0.00102	0.00879	CbGpPWpGaD
Duloxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—AGT—focal segmental glomerulosclerosis	0.00094	0.00812	CbGpPWpGaD
Duloxetine—CYP1A2—Melatonin metabolism and effects—EDN1—focal segmental glomerulosclerosis	0.0009	0.00777	CbGpPWpGaD
Duloxetine—SLC6A3—Dopaminergic Neurogenesis—TGFB1—focal segmental glomerulosclerosis	0.000889	0.00768	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—EDN1—focal segmental glomerulosclerosis	0.000863	0.00745	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—GNAQ—focal segmental glomerulosclerosis	0.000816	0.00705	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—TRPC6—focal segmental glomerulosclerosis	0.000752	0.0065	CbGpPWpGaD
Duloxetine—HTR6—GPCRs, Class A Rhodopsin-like—AGTR2—focal segmental glomerulosclerosis	0.000748	0.00646	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—AGTR2—focal segmental glomerulosclerosis	0.000748	0.00646	CbGpPWpGaD
Duloxetine—HTR2C—G alpha (q) signalling events—TRPC6—focal segmental glomerulosclerosis	0.000717	0.00619	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—AGT—focal segmental glomerulosclerosis	0.000716	0.00618	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	0.000707	0.0061	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	0.000683	0.0059	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	0.000679	0.00587	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	0.000649	0.00561	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—TRPC6—focal segmental glomerulosclerosis	0.000641	0.00554	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—AGTR2—focal segmental glomerulosclerosis	0.000641	0.00554	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—GNAQ—focal segmental glomerulosclerosis	0.000629	0.00543	CbGpPWpGaD
Duloxetine—HTR2A—G alpha (q) signalling events—TRPC6—focal segmental glomerulosclerosis	0.000623	0.00538	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—LPL—focal segmental glomerulosclerosis	0.000604	0.00522	CbGpPWpGaD
Duloxetine—HTR2C—G alpha (q) signalling events—GNAQ—focal segmental glomerulosclerosis	0.000599	0.00518	CbGpPWpGaD
Duloxetine—HTR6—GPCRs, Class A Rhodopsin-like—AGTR1—focal segmental glomerulosclerosis	0.000575	0.00497	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—AGTR1—focal segmental glomerulosclerosis	0.000575	0.00497	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	0.000571	0.00493	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—TRPC6—focal segmental glomerulosclerosis	0.000557	0.00481	CbGpPWpGaD
Duloxetine—HTR2C—GPCRs, Class A Rhodopsin-like—AGTR2—focal segmental glomerulosclerosis	0.000551	0.00476	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	0.000549	0.00474	CbGpPWpGaD
Duloxetine—HTR2C—G alpha (q) signalling events—AGTR1—focal segmental glomerulosclerosis	0.000548	0.00473	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—GNAQ—focal segmental glomerulosclerosis	0.000536	0.00463	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	0.000522	0.00451	CbGpPWpGaD
Duloxetine—HTR2A—G alpha (q) signalling events—GNAQ—focal segmental glomerulosclerosis	0.00052	0.00449	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—AGTR1—focal segmental glomerulosclerosis	0.000493	0.00426	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—focal segmental glomerulosclerosis	0.00049	0.00423	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—AGTR2—focal segmental glomerulosclerosis	0.000488	0.00422	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	0.000487	0.00421	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—NOS2—focal segmental glomerulosclerosis	0.00048	0.00414	CbGpPWpGaD
Duloxetine—HTR2A—GPCRs, Class A Rhodopsin-like—AGTR2—focal segmental glomerulosclerosis	0.000478	0.00413	CbGpPWpGaD
Duloxetine—HTR2A—G alpha (q) signalling events—AGTR1—focal segmental glomerulosclerosis	0.000476	0.00411	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—AGTR2—focal segmental glomerulosclerosis	0.000472	0.00408	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—GNAQ—focal segmental glomerulosclerosis	0.000465	0.00402	CbGpPWpGaD
Duloxetine—HTR2C—G alpha (q) signalling events—EDN1—focal segmental glomerulosclerosis	0.000465	0.00401	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	0.000443	0.00382	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—focal segmental glomerulosclerosis	0.000426	0.00368	CbGpPWpGaD
Duloxetine—HTR2C—GPCRs, Class A Rhodopsin-like—AGTR1—focal segmental glomerulosclerosis	0.000424	0.00366	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—EDN1—focal segmental glomerulosclerosis	0.000418	0.00361	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—focal segmental glomerulosclerosis	0.000416	0.00359	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—AGTR2—focal segmental glomerulosclerosis	0.00041	0.00354	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	0.000405	0.0035	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—SERPINE1—focal segmental glomerulosclerosis	0.000404	0.00349	CbGpPWpGaD
Duloxetine—HTR2A—G alpha (q) signalling events—EDN1—focal segmental glomerulosclerosis	0.000403	0.00349	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	0.000403	0.00348	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	0.000401	0.00346	CbGpPWpGaD
Duloxetine—HTR2C—G alpha (q) signalling events—AGT—focal segmental glomerulosclerosis	0.000386	0.00333	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—AGTR1—focal segmental glomerulosclerosis	0.000375	0.00324	CbGpPWpGaD
Duloxetine—HTR2A—GPCRs, Class A Rhodopsin-like—AGTR1—focal segmental glomerulosclerosis	0.000368	0.00318	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	0.000367	0.00317	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—AGTR1—focal segmental glomerulosclerosis	0.000363	0.00314	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—focal segmental glomerulosclerosis	0.000361	0.00312	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—AGTR2—focal segmental glomerulosclerosis	0.000359	0.0031	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	0.000347	0.003	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—AGT—focal segmental glomerulosclerosis	0.000347	0.003	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—focal segmental glomerulosclerosis	0.000345	0.00298	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	0.000337	0.00291	CbGpPWpGaD
Duloxetine—HTR2A—G alpha (q) signalling events—AGT—focal segmental glomerulosclerosis	0.000335	0.00289	CbGpPWpGaD
Duloxetine—SLC6A4—NRF2 pathway—TGFB1—focal segmental glomerulosclerosis	0.000329	0.00284	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—EDN1—focal segmental glomerulosclerosis	0.000318	0.00275	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—AGTR1—focal segmental glomerulosclerosis	0.000315	0.00272	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—AGTR2—focal segmental glomerulosclerosis	0.000312	0.0027	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	0.000308	0.00266	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—EDN1—focal segmental glomerulosclerosis	0.000308	0.00266	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	0.000308	0.00266	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—focal segmental glomerulosclerosis	0.0003	0.00259	CbGpPWpGaD
Duloxetine—SLC6A2—NRF2 pathway—TGFB1—focal segmental glomerulosclerosis	0.000283	0.00245	CbGpPWpGaD
Duloxetine—SLC6A2—SLC-mediated transmembrane transport—ALB—focal segmental glomerulosclerosis	0.000282	0.00244	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—TRPC6—focal segmental glomerulosclerosis	0.000277	0.0024	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—AGTR1—focal segmental glomerulosclerosis	0.000276	0.00239	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—AGTR2—focal segmental glomerulosclerosis	0.000276	0.00238	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—EDN1—focal segmental glomerulosclerosis	0.000267	0.00231	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—AGT—focal segmental glomerulosclerosis	0.000264	0.00228	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	0.000262	0.00226	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	0.000261	0.00225	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—AGT—focal segmental glomerulosclerosis	0.000255	0.00221	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—LPL—focal segmental glomerulosclerosis	0.000254	0.00219	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	0.000252	0.00218	CbGpPWpGaD
Duloxetine—SLC6A3—NRF2 pathway—TGFB1—focal segmental glomerulosclerosis	0.000251	0.00217	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—focal segmental glomerulosclerosis	0.000251	0.00217	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	0.00025	0.00216	CbGpPWpGaD
Duloxetine—SLC6A3—SLC-mediated transmembrane transport—ALB—focal segmental glomerulosclerosis	0.00025	0.00216	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	0.00024	0.00208	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—AGTR1—focal segmental glomerulosclerosis	0.00024	0.00207	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	0.00024	0.00207	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—EDN1—focal segmental glomerulosclerosis	0.000234	0.00202	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—GNAQ—focal segmental glomerulosclerosis	0.000232	0.002	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—AGT—focal segmental glomerulosclerosis	0.000222	0.00192	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—AGT—focal segmental glomerulosclerosis	0.000217	0.00187	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—AGTR1—focal segmental glomerulosclerosis	0.000212	0.00183	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	0.000211	0.00182	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—TRPC6—focal segmental glomerulosclerosis	0.000204	0.00176	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—EDN1—focal segmental glomerulosclerosis	0.000203	0.00176	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—AGTR2—focal segmental glomerulosclerosis	0.000203	0.00175	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	0.000202	0.00175	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—FN1—focal segmental glomerulosclerosis	0.000201	0.00173	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—AGT—focal segmental glomerulosclerosis	0.000195	0.00168	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	0.000193	0.00166	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	0.000192	0.00166	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	0.000186	0.0016	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	0.000184	0.00159	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	0.00018	0.00155	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—TRPC6—focal segmental glomerulosclerosis	0.000177	0.00153	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—AGTR2—focal segmental glomerulosclerosis	0.000176	0.00152	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	0.000176	0.00152	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—GNAQ—focal segmental glomerulosclerosis	0.000171	0.00148	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—AGT—focal segmental glomerulosclerosis	0.000169	0.00146	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	0.000167	0.00144	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	0.000167	0.00144	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	0.000163	0.00141	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	0.000161	0.00139	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	0.00016	0.00138	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—AGTR1—focal segmental glomerulosclerosis	0.000156	0.00135	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	0.000155	0.00134	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	0.000153	0.00132	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	0.000149	0.00129	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	0.000149	0.00129	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	0.000149	0.00129	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—GNAQ—focal segmental glomerulosclerosis	0.000148	0.00128	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	0.000148	0.00128	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	0.000143	0.00124	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	0.000142	0.00123	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—AGTR1—focal segmental glomerulosclerosis	0.000136	0.00117	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	0.000136	0.00117	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	0.000135	0.00116	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	0.000132	0.00114	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	0.000132	0.00114	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	0.000129	0.00112	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	0.000128	0.0011	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	0.000127	0.0011	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	0.000124	0.00107	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	0.000123	0.00106	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	0.00012	0.00104	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	0.000116	0.00101	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	0.000115	0.000993	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	0.000114	0.000983	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	0.00011	0.000949	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	0.00011	0.000947	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	0.000109	0.000941	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	0.000105	0.00091	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	0.000104	0.000902	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	9.98e-05	0.000862	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	9.65e-05	0.000833	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	9.55e-05	0.000824	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	9.52e-05	0.000822	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	9.46e-05	0.000817	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—LPL—focal segmental glomerulosclerosis	9.36e-05	0.000808	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	9.16e-05	0.000791	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	8.86e-05	0.000766	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	8.67e-05	0.000749	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	8.38e-05	0.000724	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	8.07e-05	0.000697	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—AGT—focal segmental glomerulosclerosis	8.01e-05	0.000692	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	7.96e-05	0.000687	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—FN1—focal segmental glomerulosclerosis	7.4e-05	0.000639	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	7.28e-05	0.000629	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	7.1e-05	0.000614	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—LIPC—focal segmental glomerulosclerosis	6.95e-05	0.000601	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	6.91e-05	0.000596	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—LPL—focal segmental glomerulosclerosis	6.89e-05	0.000595	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	6.53e-05	0.000564	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	6.17e-05	0.000533	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	6.16e-05	0.000532	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CTGF—focal segmental glomerulosclerosis	6.12e-05	0.000529	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—LPL—focal segmental glomerulosclerosis	5.99e-05	0.000517	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AGT—focal segmental glomerulosclerosis	5.9e-05	0.000509	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—LIPC—focal segmental glomerulosclerosis	5.89e-05	0.000509	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	5.67e-05	0.00049	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GNAQ—focal segmental glomerulosclerosis	5.64e-05	0.000487	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—FN1—focal segmental glomerulosclerosis	5.45e-05	0.000471	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	5.3e-05	0.000458	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CTGF—focal segmental glomerulosclerosis	5.19e-05	0.000448	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AGT—focal segmental glomerulosclerosis	5.12e-05	0.000442	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GNAQ—focal segmental glomerulosclerosis	4.78e-05	0.000413	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—FN1—focal segmental glomerulosclerosis	4.73e-05	0.000409	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	4.72e-05	0.000407	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	4.53e-05	0.000392	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—LPL—focal segmental glomerulosclerosis	4.24e-05	0.000367	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	3.94e-05	0.00034	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	3.89e-05	0.000336	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—AGT—focal segmental glomerulosclerosis	3.63e-05	0.000314	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—LPL—focal segmental glomerulosclerosis	3.59e-05	0.000311	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	3.47e-05	0.0003	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—AGT—focal segmental glomerulosclerosis	3.08e-05	0.000266	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	3.02e-05	0.00026	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	2.86e-05	0.000247	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ALB—focal segmental glomerulosclerosis	2.79e-05	0.000241	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	2.49e-05	0.000215	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ALB—focal segmental glomerulosclerosis	2.36e-05	0.000204	CbGpPWpGaD
